Portugal Pharmaceuticals & Healthcare Report Q4 2014 - New Market Report

From: Fast Market Research, Inc.
Published: Thu Nov 06 2014

Despite Portugal's stronger-than-expected economic expansion in previous quarters, government austerity measures will continue to weigh on drug spending over the medium term. This is reflected i n recent agreements between the Portuguese government and the pharmaceutical industry to reduc e public spending o n medicines and on expected incentives for pharmacies to increase the use of generics. Meanwhile, rapid growth in the Portuguese private healthcare sector suggests eventual opportunities in this market, as illustrated by recent takeover bid s for Espirito Santo Saude . In the public sector, a gainst a backgrou nd of mounting arrears in state- own ed hospitals, as well as healthcare workers protests due to personnel shortage and pressure from the pharmaceutical industry over payment delays, the Portuguese government will struggle to find an appropriate balance for health financing in the next quarters, notwithstanding the announced health budget strengthening for 2015.

Full Report Details at
- http://www.fastmr.com/prod/888573_portugal_pharmaceuticals_healthcare_report_q4.aspx?afid=301

Headline Expenditure Projections

* Pharmaceuticals: EUR3.48bn (USD4.59bn) in 2013 to EUR3.25bn (USD4.36); -6.5% in local currency and -5.1% in US dollar terms. Forecast revised slightly downwards from Q314 due to macroeconomic factors.
* Healthcare: EUR15.00bn (USD19.80bn) in 2013 to EUR14.98bn (USD20.08bn) in 2014; -0.1% in local currency and +1.4% in US dollar terms. Forecast revised downwards from Q314 due to revision to historic data.

Risk/Rewards Rating

In Q414 Portugal remains situated at the bottom of our Pharmaceutical Risk/Reward Rating (RRR) for Western Europe, with a score of 57.7 out of 100. We have slightly upgraded Portugal's RRR score to 58.9 from 57.7 in the previous quarter due to revision to historic data. Portugal posts below regional average scores for all indicators.

Key Trends & Developments

* In September 2014 the Portuguese private healthcare firm Jose de Mello Saude launched a takeover bid for its rival Espirito Santo Saude...

The Portugal Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Portugal Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Portuguese pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Portugal to test other views - a key input for successful budgeting and strategic business planning in the Portuguese pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Greece Pharmaceuticals & Healthcare Report Q4 2014
- Saudi Arabia Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »